Primary adrenal nodular lymphocyte‑predominant Hodgkin lymphoma: A case report and review of the literature

Wang,Jingjing; Ma,Jin'an; Hu,Chunhong; Li,Daiqiang; She,Xiaoling

doi:10.3892/ol.2014.2289

Primary adrenal nodular lymphocyte‑predominant Hodgkin lymphoma: A case report and review of the literature

Authors:
- Jingjing Wang
- Jin'an Ma
- Chunhong Hu
- Daiqiang Li
- Xiaoling She
View Affiliations

Affiliations: Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China
Published online on: June 26, 2014 https://doi.org/10.3892/ol.2014.2289
Pages: 1147-1150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nodular lymphocyte‑predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma (HL), and is a rare disease manifestation in the adrenal gland, which is difficult to be diagnosed and treated. In the present study, we report a case of primary adrenal NLPHL in a 36‑year‑old male patient. The patient was without specific clinical signs and the definitive diagnosis was achieved by histological study. The patient underwent a laparoscopic left adrenalectomy and chemotherapy regimen of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). There is no standard treatment for adrenal NLPHL and therefore, treatment is based on that for other types of NLPHL, which includes radiotherapy and ABVD chemotherapy. Given the rarity of this disease, there are limited experiences with regard to its diagnosis and treatment. This study is useful for the differential diagnosis and treatment of adrenal masses.

View Figures

View References

1	Nogová L, Rudiger T and Engert A: Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:266–272. 2006.
2	Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z and Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res. 14:411–421. 2008.
3	Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD and Connors JM: Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 118:4585–4590. 2011.
4	Chen RC, Chin MS, Ng AK, et al: Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 28:136–141. 2010.
5	Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B and Savage KJ: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol. 28:793–799. 2010.
6	Biasoli I, Stamatoullas A, Meignin V, et al: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 116:631–639. 2010.
7	Nogová L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 26:434–439. 2008.
8	Harris NL, Jaffe ES, Diebold J, et al: World Health Organization Classification of neoplastic diseases of hematopoetic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999.
9	Xing KH, Connors JM, Lai A, et al: The outcome of advanced stage nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) compared to classical Hodgkin’s lymphoma (CHL): a matched pair analysis. Blood. 123:3567–3573. 2014.
10	Hagspiel KD: Manifestation of Hodgkin’s lymphoma in an adrenal myelolipoma. Eur Radiol. 15:1757–1759. 2005.
11	Bourne AE, Bell SW, Wayment RO and Schwartz BF: Primary Hodgkin lymphoma of the adrenal gland: a unique case presentation. Cn J Urol. 16:4694–4696. 2009.
12	Szczepanowski M, Masqué-Soler N, Oschlies I, Schmidt W, Lück A and Klapper W: Composite lymphoma of nodular lymphocyte-predominant and classical Hodgkin lymphoma-Epstein-Barr virus association suggests divergent pathogenesis despite clonal relatedness. Hum Pathol. 44:1434–1439. 2013.
13	Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 379:1791–1799. 2012.
14	Anagnostopoulos I, Hansmann ML, Franssila K, et al: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 96:1889–1899. 2000.
15	Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, et al: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 118:4363–4365. 2011.
16	Eichenauer DA, Engert A and Dreyling M; ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6): Svi55–Svi58. 2011.
17	Wirth A, Yuen K and Barton M: Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 104:1221–1229. 2005.
18	Nogova L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from German Hodgkin Study Group (GHSG). Ann Oncol. 16:1683–1687. 2005.
19	Specht L, Yahalom J, Illidge T, et al: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. DOI: 10.1016/j.ijrobp.2013.05.005
20	Savage KJ, Hoskins P, Klasa R, et al: ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin lymphoma. Hematologica. 92(Suppl 5): 27–28. 2007.
21	Meyer RM, Gospodarowicz MK, Connors JM, et al: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group: ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 366:399–408. 2012.
22	Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al: Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection - a Study of the French Society of Pediatric Oncology. J Clin Oncol. 21:2948–2952. 2003.
23	Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 110:179–185. 2007.
24	Ekstrand BC, Lucas JB, Horwitz SM, et al: Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 101:4285–4289. 2003.
25	Schulz H, Rehwald U, Morschhauser F, et al: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 111:109–111. 2008.
26	Hoppe RT, Advani RH, Ai WZ, et al: Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 10:589–597. 2012.